BioSpace News Archive

The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of Menarini Group, announced that the U.S. Food and Drug Administration has accepted the Company’s New Drug Application for elacestrant, an investigational selective estrogen receptor degrader, for patients with ER+/HER2- advanced or metastatic breast cancer.

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its pipeline programs.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, reported financial results for the quarter ending June 30, 2022.

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, reported financial results for the second quarter of 2022 and provided an update on recent corporate and clinical developments.

Mustang Bio, Inc. announced financial results and recent corporate highlights for the second quarter ended June 30, 2022.

Agile Therapeutics, Inc., a women’s healthcare company, reported financial results for the three months ended June 30, 2022 and provided a corporate update.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company, provided a business update and reported financial results for the second quarter June 30, 2022.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the second quarter of 2022.

Histogen Inc. (NASDAQ: HSTO), today reported financial results for the second quarter ended June 30, 2022 and provided an update on its clinical pipeline and other corporate developments.